Shijiazhuang No.4 Pharmaceutical Group Ltd is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products and medical packaging materials. It ranks among the top 100 enterprises in China's pharmaceutical industry and the excellent export-oriented enterprises in chemical and pharmaceutical preparation industry. In 2007, the company was listed on the main board of Hong Kong (SSY Group Limited, 02005.HK).
For more than 70 years, the Group has braved the wind and rain and forged ahead. Especially in the past 20 years, under the leadership of Mr. Qu Jiguang, the Group has changed from a small workshop to a large listed company, and the enterprise has achieved a fundamental change and qualitative leap.
At present, the Group has 10 subsidiaries with more than 6,500 employees, assets of 10 billion RMB and main business income of more than 6 billion RMB. It has a multi-category business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological pharmaceutical products and medical packaging materials. The Group has formed an entire industrial chain of R&D, production and application of characteristic APIs, new preparations, and medical packaging materials. The annual production capacity of injection products can reach 4 billion bottles/bags, and the production scale and technical level are among the best in China.